Xarelto lawsuits continue to mount in the federal multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana. According to a report issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) on July 15th, hundreds of new cases were filed in the centralized proceeding over the past month.
The report indicates that there are now 6,457 Xarelto injury claims pending in the Eastern District of Louisiana. That’s an increase of more than 1,200 cases since June 15th, when the JPML reported 5,250 filings.
All of the Xarelto lawsuits pending in the Eastern District of Louisiana were filed on behalf of patients who suffered internal bleeding and other complications allegedly due to their use of the blood-thinning medication. Among other things, plaintiff’s charge that the drug’s manufacturers have wrongly promoted Xarelto as a superior alternative to warfarin ever since the new-generation anticoagulant was approved by U.S. health regulators in 2011. Among other things, the complaints note that internal bleeding associated with warfarin can be stopped via the administration of vitamin K. However, there currently exits no antidote for reversing Xarelto bleeding side effects when they occur.
The first Xarelto lawsuits are expected to head to trial in Louisiana this coming February. Verdicts in these bellwether trials, which will involve cases representative of others in the proceeding, are expected to provide some insight into how juries might decide similar Xarelto claims. A reports filed with the Court in advance of the litigation’s July 6th Status Conference indicated that discovery in 40 cases selected as possible bellwether trial candidates is currently moving forward.
The proceeding’s next Status Conference is schedule for August 4, 2016 at 9:00 a.m.